Status:

UNKNOWN

Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae

Lead Sponsor:

Phramongkutklao College of Medicine and Hospital

Conditions:

Drug Resistance

Carbapenem-Resistant Enterobacteriaceae Infection

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.

Detailed Description

Antibiotic resistance is one of the major problems because of global burden. Resistant pathogens are non-susceptible to available antibiotics, causing of high clinical mortality (clinical impact) and ...

Eligibility Criteria

Inclusion

  • Any patients are diagnosed any diseases caused by CRE infection by physicians at Phramongkutklao hospital during 1/4/2018 to 30/4/2021.
  • Any patients are more than 18 years old.
  • Any patients have at least 1 criterion as following 3.1 Any patients have at least 2 of the signs and symptoms of Systemic inflammatory response syndrome (SIRS), including
  • Fever (temperature \> 38 °C) or hypothermia (temperature \< 36°C)
  • Tachypnea (heart rate \> 90 beats per minute)
  • Respiratory rate \> 20 beats per minute or Paco2 \< 32 mm Hg (4.3 kPa)
  • White blood cell count \> 12,000 cells per millilitre (leukocytosis) or \< 4,000 cells per milliliter (leukopenia) 3.2. Any patients are diagnosed with sepsis or have ≥ 2 points of Sequential Organ Failure Assessment (SOFA) Score or qSOFA (Quick SOFA) Score.
  • 3. Any patients are diagnosed with septic shock or are received vasopressors (eg, dopamine, norepinephrine, epinephrine, vasopressin, phenylephrine), mean arterial pressure (MAP) \< 65 mm Hg, and lactate \> 2 mmol/L (18 mg/dL) 3.4 Any patients are received mechanical ventilation 3.5 Any patients are admitted at ICU ward.

Exclusion

  • Patients are breast-feeding or pregnancy.
  • Patients are insufficient or incomplete information on the medical electronic record such as patients transferred.

Key Trial Info

Start Date :

September 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2021

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT04516395

Start Date

September 1 2020

End Date

April 1 2021

Last Update

August 26 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Phramongkutklao hospital

Bangkok, Thailand, 10400